Clinical trial
Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer
NCT00280930 · Dana-Farber Cancer Institute, Other · Unknown status
Key facts
| NCT number | NCT00280930 |
|---|---|
| Title | Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer |
| Official title | A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Post-Menopausal, Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 60 |
| Start date | Oct 1, 2005 |
| First posted | Jan 24, 2006 |
| Last update posted | Jan 19, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: